Joe Biden Visits Clay Siegall’s Seattle Genetics

Clay B. Siegall is a successful biotechnologist in the world. He is the founder and chief executive officer of Seattle Genetics, a biotechnology company that specializes in cancer therapies. Siegall also serves as the president and chairman of the company too. He is in charge of the company operations, and he also organizes the capital raising activities of the institution.

The first drug from Seattle Genetics is called Adcetris. Since it was introduced in the market, the cancer drug has done quite well, and it has been used to cure more than fifteen thousand lymphoma patients in the globe. The company is planning to increase its therapies very soon, and more patients will be able to get treatment.

Seattle Genetics recently got a rare visit from Joe Biden, the Vice President of the US. During the tour, Seattle Genetics and its founder were put in the limelight, and many people were able to recognize the institution as one of the fastest growing biotechnology companies in the United States. The products from the company are already being used in more than sixty nations around the globe, and more people are getting cured thanks to the therapies from the enterprise.

During the visit by the vice president, Seattle Genetics announced its plans of introducing more employees in the next five years. These employees will help the company in developing more drugs for different types of cancers. To make this dream a reality, Seattle Genetics managed to raise more capital, and Clay says that the money raised will be used in making sure that the company achieves its goals.

Mirna Therapeutics, one of the leading biotechnology companies in the world decided to introduce Clay Siegall in its board of directors. The institution recently announced that Clay Siegall would be serving Mirna Therapeutics as an outside director. The biotechnology company hired the successful Siegall because he has a lot of experience in cancer treatments, and he will play a crucial role in advancing the therapeutics from Mirna. The management of the company is excited to work with Siegall because they know that he is the right person for the job.